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Patients without colonoscopic follow-up
after abnormal fecal immunochemical tests
are often unaware of the abnormal result
and report several barriers to colonoscopy
Vivy T. Cusumano1, Edgar Corona1,2, Diana Partida1, Liu Yang1,2, Christine Yu1,3 and Folasade P. May1,2,4,5*
Abstract
Background: The fecal immunochemical test (FIT) is the second most commonly used colorectal cancer (CRC)
screening modality in the United States; yet, follow-up of abnormal FIT results with diagnostic colonoscopy is
underutilized. Our objective was to determine patient-reported barriers to diagnostic colonoscopy following
abnormal FIT in an academic healthcare setting.
Methods: We included patients age 50–75 with an abnormal FIT result between 1/1/2015 and 10/31/2017 and no
documented follow-up diagnostic colonoscopy. We abstracted demographic data from the electronic health record
(EHR). Study personnel conducted telephone surveys with patients to confirm colonoscopy completion and elicit
data on notification of FIT results and barriers to colonoscopy. We also provided brief verbal education about
diagnostic colonoscopy. We calculated frequencies of demographic data and survey responses and compared
survey responses by interest in colonoscopy after education.
Results: We surveyed 67 patients. Fifty-one were aware of the abnormal FIT result, and a majority learned of the
abnormal FIT result by direct communication with providers (19, 37.3%) or EHR messaging (11, 21.6%). Overall, fifty-
three patients (79.1%) confirmed lack of colonoscopy, citing provider-related (19, 35.8%), patient-related (16, 30.2%),
system-related (1, 1.9%), or multifactorial (17, 32.1%) reasons. Lack of knowledge of FIT result (14, 26.4%) was most
common. After brief education, 20 (37.7%) patients requested colonoscopy.
Conclusion: Patients with an abnormal FIT reported various multi-level barriers to diagnostic colonoscopy after
abnormal FIT, including knowledge of FIT results. When provided with brief education, participants expressed
interest in diagnostic colonoscopy. Future efforts will evaluate interventions to improve colonoscopy follow-up.
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Background
Colorectal cancer (CRC) is the second leading cause of
cancer-related mortality in the United States (U.S.) and
accounts for 8.3% of cancer deaths overall [1, 2]. The
disease is largely preventable by screening, and early de-
tection improves outcomes. Over 90% of individuals
with stage I disease will survive at least 5 years, com-
pared to less than 15% of those diagnosed at an ad-
vanced stage [3, 4]. The United States Preventative
Services Task Force (USPSTF) reaffirmed the import-
ance of CRC screening in their 2016 screening guide-
lines, making a grade A recommendation to screen all
average-risk individuals age 50 to 75 and outlining sev-
eral screening strategies. One of the recommended
screening modalities, the fecal immunochemical test
(FIT), is a commonly used, noninvasive, and inexpensive
screening option with high participation rates [5–8]. Ac-
cordingly, the most recent Multi-Society Task Force
(MSTF) CRC screening guidelines recommend FIT as
one of two first-tier screening tests along with colonos-
copy [9].
The FIT detects the globin portion of human
hemoglobin in stool. Individuals with evidence of globin
in the stool must undergo diagnostic colonoscopy to
determine if there is a precancerous and/or cancerous
lesion in the colon that has led to the abnormal (i.e.
positive) result. While abnormal FIT results may repre-
sent benign lesions (i.e. hemorrhoids, hyperplastic
polyps, normal colon), follow-up testing with colonos-
copy aims to detect adenomas and colorectal carcinoma
[7, 8]. Thus, FIT is a two-step screening process that is
only effective when those with abnormal results undergo
colonoscopy.
Despite these fundamental aspects of FIT screening,
CRC screening programs struggle to achieve high rates
for colonoscopic follow-up after abnormal FIT results.
Across healthcare settings in the U.S., follow-up rates
are far below the national benchmark of 80% colonos-
copy completion after abnormal FIT [10–13]. Patients
with an abnormal FIT have a CRC prevalence of 2.9 to
7.8% [8, 14]. Low follow-up rates are associated with late
stage CRC at diagnosis and CRC-related death [8, 15–
19]. Lack of follow-up also reduces the cost-effectiveness
of screening and worsens inequities in CRC screening
and CRC outcomes [20, 21].
Prior studies have identified low rates of colonoscopic
follow-up after abnormal FIT and predictors of lack of
follow-up [11, 12, 14, 22]. However, much of the existing
literature relies on electronic health record (EHR) data
to determine facilitators and barriers to colonoscopic
follow-up, which is susceptible to provider bias and in-
complete documentation [23]. Fewer studies have con-
sidered patient perspectives to evaluate comprehension
of FIT results and to understand barriers to follow-up.
Thus, we aimed to speak directly with patients in our
health system with an abnormal FIT to characterize
patient-reported barriers to diagnostic colonoscopy. As
improving FIT follow-up rates is a priority in our health
center, the work will help to identify unrecognized fac-
tors impeding FIT follow-up and guide the development
of interventions to improve completion of CRC
screening.
Methods
Study setting and population
This retrospective cohort study was conducted at Uni-
versity of California Los Angeles (UCLA) Health, a large,
integrated academic tertiary care center in Southern
California with a defined primary care population and
robust referral-based care. The primary care population
includes over 350,000 enrollees who exclusively receive
coverage for care services at UCLA. In this setting, CRC
screening and follow-up after abnormal FIT are man-
aged by primary care providers. System-wide policy rec-
ommends CRC screening for all adults age 50 to 75, and
multiple screening strategies are available with FIT (9%)
and colonoscopy (85%) being the most common. If the
FIT is abnormal, the primary care provider receives noti-
fication of the abnormal result and is responsible for
generating a referral to gastroenterology for
colonoscopy.
With assistance from our institution’s Clinical and
Translational Science Institute (CTSI), we queried EHR
data to identify patients who met the following inclusion
criteria: 1) age 50–75, 2) assignment to a UCLA primary
care provider, 3) abnormal FIT result between 1/1/2015
and 10/31/2017, and 4) lack of EHR documentation of a
diagnostic colonoscopy 6 months after the abnormal FIT
(as consistent with other studies in the literature) [10].
Patients were excluded if they had a history of Crohn’s
disease, ulcerative colitis, prior colectomy, and/or a per-
sonal history of CRC. Patients with a family history of
CRC are not screened with FIT in our health system.
Study instrument and survey procedures
Three study personnel (V.T, E. C, and D.P) contacted all
eligible patients via telephone between 8/10/18 and 9/
17/18. All personnel underwent training on FIT process-
ing and FIT guidelines prior to study initiation and par-
ticipated in meetings to discuss the study protocol and
survey instrument [8, 9]. Patient telephone numbers
were obtained from the EHR, and study personnel
attempted to reach each patient a maximum of 5 times.
All patients provided verbal informed consent for par-
ticipation in the study. Once verbal consent was ob-
tained, study personnel administered a telephone survey
containing 8 items. For patients that declined the survey
invitation, we obtained a reason for the survey decline.
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The survey instrument employed two modules to elicit
data on 1) knowledge and notification of FIT results, 2)
colonoscopy completion, 3) barriers to diagnostic colon-
oscopy, and 4) interest in colonoscopy after brief educa-
tion (Table 1). Study personnel followed a script to
administer the survey and to provide brief (i.e. approxi-
mately 2 min) standardized education on the purpose of
a FIT test, recommendations after an abnormal result,
and details of the colonoscopy procedure. The final sur-
vey items asked participants if they would like to be con-
tacted to schedule a colonoscopy or primary care
provider appointment. If participants declined, we asked
the participant to report the reason for the decline. This
survey instrument was informed by existing literature,
reviewed by four independent study personnel, and
piloted prior to use. We confirmed patient report of col-
onoscopy completion with EHR data.
For each participant, we also obtained demographic
data (age, sex, race, ethnicity, marital status, and in-
surance status at time of abnormal FIT) and method
of notification of FIT result from the EHR. Six
months after the survey, we performed a second man-
ual chart review to determine whether participants
completed diagnostic colonoscopy and/or a visit with
their provider after participating in the survey. Find-
ings of completed colonoscopies were also obtained
from chart review.
Statistical analysis
We first used frequencies and means (± standard devi-
ation) to summarize participant demographic data. We
then used chi-square and student t-tests to compare
demographics for those that did and did not participate
in the survey. Those who refused participation in the
study or could not be reached by telephone were ex-
cluded from further analyses.
We next determined response frequencies for each
survey item and stratified these responses by patient-
reported colonoscopy completion status. For those who
did not complete a colonoscopy, we calculated frequen-
cies for the main reason for lack of colonoscopy. We
also performed chi-square tests, Fisher’s exact tests, and
student t-tests to compare patient characteristics be-
tween those who requested and declined colonoscopy
after the brief education. All statistical analyses were
performed with SAS version 9.4. A p-value less than
0.05 was considered statistically significant. This study
was reviewed and approved by the Institutional Review
Board at UCLA.
Results
Descriptive characteristics of the study population
We contacted 148 patients, and 67 (45.3%) completed
the survey (Fig. 1). For those that participated in the sur-
vey, the mean age was 63 years, 52.2% were male, and
61.2% were white. The majority of participants were
married (65.7%), and 92.5% had medical insurance. The
employment rate was 44.8, and 37.3% were retired
(Table 2).
Those who did not participate in the survey (n = 81)
did not answer the telephone (55, 67.9%), answered the
telephone but declined participation (17, 20.9%), had
phone numbers no longer in service (5, 6.1%), or were
deceased at the time of the study (4, 4.9%). Demographic
characteristics were similar among those who did and
did not complete the survey (Table 2).
Notification of FIT result and colonoscopy completion
status
Of the 67 patients that participated in the survey, 51
(76.1%) were aware of their abnormal FIT result. Of
these 51, most reported learning of their abnormal FIT
result through direct communication with the ordering
Table 1 Patient survey items
Survey Item
Module 1: Knowledge of result, notification of result, and colonoscopy status
Knowledge of FIT result “How did you learn about the result of your take home colon cancer screening stool test?”
Colonoscopy completion status “Did you have a colonoscopy after your abnormal stool test result?”
Colonoscopy date (if completed) “What was the date of your colonoscopy?”
Colonoscopy location (if completed) “Where did you have the procedure done?”
Module 2: Barriers to diagnostic colonoscopy and colonoscopy education
Main reason for lack of follow-up “What would you say is the main reason why you did not have a colonoscopy after your
abnormal stool test?”
Interest in colonoscopy (after brief education) “Would it be okay for a UCLA scheduler to contact you to schedule your colonoscopy?”
Reason for not scheduling colonoscopy
(if colonoscopy declined)
“Please share with me why you don’t want to schedule a colonoscopy”
Interest in primary care provider appointment
(if declined colonoscopy)
“Would it be okay for a UCLA scheduler to contact you to schedule an appointment with
your primary care provider?”
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provider (19, 37.3%) or EHR messaging through the on-
line patient-provider portal (11, 21.6%). Other mecha-
nisms of notification included: mail (2, 3.9%), phone call
by a nurse (5, 9.8%), or could not recall (14, 27.4%).
When asked about colonoscopy status, 53 of the 67
participants (79.1%) reported that they did not complete
a colonoscopy after the abnormal FIT, 11 (16.4%) re-
ported colonoscopy completion, and 3 (4.5%) were un-
certain if they had a colonoscopy after the abnormal
FIT. Of the 11 (16.4%) that reported colonoscopy com-
pletion after abnormal FIT, 6 did so at our health center
after study initiation but prior to administration of our
survey and 5 completed an outside facility colonoscopy
that was not documented in the EHR.
Reasons for lack of colonoscopy
We asked the 53 participants that did not complete col-
onoscopy after an abnormal FIT to state the one main
reason for lack of colonoscopy. We categorized these
reasons as provider-related (19, 35.8%), patient-related
(16, 30.2%), system-related (1, 1.9%), or multifactorial
(17, 32.1%) (Fig. 2). Patient-related reasons included pa-
tient fear and/or anxiety about colonoscopy (5, 9.4%) or
believing the colonoscopy was not important (5, 9.4%).
Among the provider-related reasons, primary reasons
were lack of provider recommendation for follow-up
colonoscopy (12, 22.6%) and provider recommendation
against colonoscoy due to previous normal colonoscopy
(5, 9.4%). The 1 (1.9%) participant who reported health-
care system-level barriers experienced challenges sched-
uling the colonoscopy procedure. There were 17
participants (32.1%) with multifactorial reasons: 14
(26.4%) reported that the survey was the first time they
were made aware of their abnormal FIT result, 2 (3.8%)
had a CT colonography instead of colonoscopy as the
follow-up examination due to other comorbidities, and 1
(1.9%) was awaiting an upcoming scheduled
colonoscopy.
Fourteen (26.4%) of the 53 survey participants that did
not complete colonoscopic follow-up reported no know-
lege of the abnormal FIT results at the time of the sur-
vey. Interestingly, 13 of the 14 (92.9%) did have
physician or nurse EHR documentation that the abnor-
mal FIT result was discussed with the patient.
Interest in colonoscopy after education
After the scripted education about FIT testing and colon-
oscopy, 20 of 53 (37.7%) participants requested to be
scheduled for colonoscopy. There were no significant dif-
ferences in sociodemographic characteristics between
those who did and did not want to be scheduled (Table 3).
The 33 participants who declined to be scheduled for
Fig. 1 Survey participants
Cusumano et al. BMC Gastroenterology          (2020) 20:115 Page 4 of 9
colonoscopy noted several reasons for the decline: 11
(33.3%) expressed a desire to speak to their primary care
provider before proceeding with colonoscopy, 9 (27.3%)
reported it was not recommended by their provider, 6
(18.2%) cited other health issues or priorities as reasons to
postpone the exam, 3 (9.1%) changed locations, and 4
(12.1%) had other reasons. Chart review 6 months after
the survey was administered revealed that 33 (62.3%) of
the 53 patients that reported no colonoscopy at the time
of the survey had further action on the abnormal FIT re-
sult after scripted education: 6 completed colonoscopy, 8
had a pending gastroenterology or colonoscopy appoint-
ment, and 19 had further discussion with their primary
care provider. Of the 6 patients who completed colonos-
copy, results were: normal (1), non-advanced adenoma
(2), and advanced adenoma (3).
Discussion
Patients reported several multi-level reasons for lack
of follow-up colonoscopy after abnormal FIT. These
findings are consistent with studies that use EHR data
to demonstrate various reasons for lack of follow-up
but also highlight additional factors that play a role
in poor follow-up after abnormal FIT, including lack
of awareness of the FIT result and suboptimal com-
munication around scheduling and colon preparation.
Our study emphasizes the need for multi-level inter-
ventions to achieve the MSTF benchmark that 80% of
patients with an abnormal FIT undergo colonoscopy
[11, 12, 22, 24, 25].
We found that patients with an abnormal FIT and no
colonoscopic follow-up were often unaware of the result.
Lack of knowledge of the FIT result was the most
Table 2 Descriptive characteristics of survey participants and survey non-participants; N = 148
Patient characteristic Survey participants (n = 67) Survey non-participants (n = 81) p-value*
Age (Mean ± s.d.) 63 ± 7.0 63 ± 6.9 0.58
Sex
Male 35 (52.2%) 44 (54.3%) 0.79
Female 32 (47.8%) 37 (45.7%)
Race/Ethnicity
White (non-Hispanic) 41 (61.2%) 47 (58.0%) 0.20
Black (non-Hispanic) 4 (6.0%) 8 (9.9%)
Hispanic 5 (7.5%) 0 (0.0%)
Asian (non-Hispanic) 8 (11.9%) 10 (12.4%)
Other (non-Hispanic) 7 (10.4%) 9 (11.1%)
Unknown (non-Hispanic) 2 (3.0%) 7 (8.6%)
Marital Status
Married 44 (65.7%) 47 (58.0%) 0.40
Single 22 (32.8%) 32 (39.5%)
Unknown 1 (1.5%) 2 (2.0%)
Employment
Employed 30 (44.8%) 28 (40.6%) 0.79
Unemployed 10 (14.9%) 12 (17.3%)
Retired 25 (37.3%) 29 (42.0%)
Unknown 2 (3.0%) 12 (14.8%)
Medical Insurance
Yes 62 (92.5%) 74 (91%) 0.81
No/Uncovered/Self-Pay 4 (6.0%) 7 (8.6%)
Unknown 1 (1.5%) 0 (0.0%)
Colonoscopy completed
Yes 11 (16.4%) – –
No 53 (79.1%)
Don’t Know 3 (4.5%)
s.d., standard deviation
*p-values compare survey participants to non-participants
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Fig. 2 Reported main reason for lack of diagnostic colonoscopy after abnormal FIT among participants without colonoscopy* (n = 53)
Table 3 Comparison of survey participants eligible for diagnostic colonoscopy stratified by interest in colonoscopy, n = 53
Patient characteristic Requested colonoscopy (n = 20) Declined colonoscopy (n = 33) p-value
Age (Mean ± s.d.) 64 ± 7 64 ± 7 1.00
Sex 0.91
Male 10 (50.0%) 17 (51.5%)
Female 10 (50.0%) 16 (48.5%)
Race/Ethnicity 0.24
White 10 (50.0%) 22 (66.7%)
Non-White 9 (45.0%) 10 (30.3%)
Unknown 1 (5.0%) 1 (3.0%)
Marital Status 0.85
Married 12 (60.0%) 20 (60.6%)
Single 8 (40.0%) 12 (36.4%)
Unknown 0 (0.0%) 1 (3.0%)
Employment 0.28
Employed 10 (50.0%) 14 (42.5%)
Unemployed 1 (5.0%) 7 (21.2%)
Retired 9 (45.0%) 11 (33.3%)
Unknown 0 (0.0%) 1 (3.0%)
Medical Insurance 1.00
Yes 18 (90.0%) 30 (90.9%)
No/Uncovered/Self-Pay 1 (5.0%) 3 (9.1%)
Unknown 1 (5.0%) 0 (0.0%)
s.d., standard deviation
*p-values compare participants who requested colonoscopy to participants who declined colonoscopy
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common patient-reported reason for lack of follow-up,
occurring in 26.4% of participants despite EHR docu-
mentation that the results were discussed with a pro-
vider for the large majority. While it is possible that
providers documented a discussion that did not take
place, it is also possible that patients had poor recall of
discussions with providers after the abnormal FIT. This
is not entirely surprising as 40-80% of medical informa-
tion provided by healthcare practitioners is forgotten im-
mediately [26, 27]. Factors that contribute to poor recall
of medical information include clinician factors (use of
medical terminology, amount of information relayed),
mode of communication (verbal compared to written),
and factors related to the patient (perceived importance,
anxiety or stress, age) [27, 28]. As lack of knowledge of
the abnormal result was the most common reason for
lack of colonoscopy in this cohort, our findings highlight
the importance of clear and purposeful information
transfer and counseling regarding FIT results. The in-
consistency between provider documentation and pa-
tient recall also underscores opportunities for improved
tracking, navigation, and communication as patients
move through the FIT screening process.
Patient- and provider-related barriers were the most
common reasons for lack of colonoscopy. Patient-level
barriers included fear of the procedure and the bowel
preparation and low priority, which is consistent with
prior literature [12, 22, 29]. Provider-related reasons in-
cluded lack of provider recommendation for colonos-
copy, previously normal colonoscopy, or a repeated stool
screening test that was normal. They reflect provider
uncertainty about appropriate use of FIT and chal-
lenges navigating discussions with patients hesistant
about colonoscopy [29, 30]. The existing literature
documents recent normal colonoscopy as a common
reason for lack of colonoscopy after abnormal FIT or
fecal occult blood test (FOBT) [14, 22]. However, the
MSTF recommendation is to offer repeat colonoscopy
even in the setting of a recent study, as the risk of
CRC and advanced colorectal neoplasia remains not-
able even among those with recent colonscopy [8,
31]. These patient- and provider-related barriers are
likely exacerbated by other system-related factors like
the scheduling difficulties we observed. Interventions
that include patient navigators to provide a targeted
and individualized approach to address these emo-
tional and structural multi-level barriers may further
improve follow-up rates [25, 32]. Our very limited
outreach and education about FIT and diagnostic col-
onoscopy generated interest and further action follow-
ing abnormal FIT. However colonoscopy completion
at 6 months remained low, further supporting the
need for repeated patient outreach and personalized
assistance to improve colonoscopic follow-up.
Our study is not without limitations. First, our study
population was a majority insured patient population in
a tertiary care center. Thus, our findings may not be
generalizable to uninsured patients or to other health-
care settings. Nonetheless, our cohort was diverse, and
the study design allowed us to focus on patient’s per-
ceived barriers to colonoscopic follow-up beyond cost
and insurance. Second, we were limited by our small
sample size. However, to date, our study remains one of
few to interview patients with an abnormal FIT and pre-
vious studies exploring patient perspectives are often
small [29, 33]. Third, our study was limited in its scope
and relies on patient recollection of events, which may
be susceptible to response bias, memory bias, or poor re-
call. However, this limitation only highlights the need
for future research to better understand challenges from
the perspective of the patient and provider, especially as
it pertains to communication about FIT results.
Despite these limitations, our study has many
strengths. First, we directly interviewed patients to elicit
their knowledge, attitudes, and beliefs about FIT screen-
ing and completing the FIT screening process. We were
also able to ask patients about the main reason for lack
of colonoscopic follow-up after abnormal FIT. Prior re-
search in this area relies on chart review, in which this
information is often undocumented, can be documented
erroneously, or may fail to capture true patient barriers
[22, 34]. Second, we highlight an area that is important
and understudied. While many studies focus on CRC
screening uptake, fewer explore poor follow-up after ab-
normal FIT despite evidence that abnormal FIT results
are related to poor CRC outcomes [35, 36]. FIT screen-
ing programs are only successful if patients with abnor-
mal results complete colonoscopy. Third, our findings
improve our understanding of patient-reported barriers
and provide information that will guide the development
of future interventions to address barriers to colonos-
copy. Lastly, we demonstrate that interest in diagnostic
colonoscopy can be high, even among patients that failed
to complete colonoscopic follow-up early. As a result,
we are designing a telephone-based navigation interven-
tion for patients with an abnormal FIT in our health
system.
Our study has several implications for patients, pro-
viders, health care systems, and policymakers. Poor
follow-up after abnormal FIT is a problem and places
patients at increased risk for poor outcomes [10, 35].
Many patients are unaware of their FIT result, so pro-
viders must engage in improved counseling and repeated
discussion to encourage follow-up. Clear explanation of
FIT as a two-step screening process at the time of FIT
prescription and addressing abnormal FIT results early
may improve follow-up. Timeliness of follow-up is also
critical as data suggest that follow-up more than 10
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months after an abnormal FIT is associated with up to
50% higher risk of CRC and more advaned-stage disease
at the time of diagnosis [18]. Concerning healthcare pol-
icy, we must increase attention nationally to these chal-
lenges in the cancer care continuum. Currently, the
focus remains on CRC screening uptake, with mandated
reporting of CRC screening rates through regulatory ef-
forts like Healthcare Effectiveness Data and Information
Set (HEDIS). Without a similar emphasis on completion
of screening, it is unlikely that health systems will
achieve high colonoscopic follow-up rates. Quality and
health policy experts should consider mechanisms for
reporting and monitoring rates of diagnostic colonos-
copy after abnormal FIT to maximize the quality of CRC
screening programs and improve CRC outcomes.
Conclusions
Our study identified several patient-reported challenges
to diagnostic colonoscopy after abnormal FIT among
those without colonoscopic follow-up. Future research
should include qualitative studies with patients and their
providers to better characterize challenges discussing
FIT results and the importance of colonoscopy. Patients
might benefit from understanding upfront that abnormal
FIT results require additional evaluation, and the med-
ical community might benefit from additional education
about the appropriate use of FIT, repeat FIT testing, and
recommendations for colonoscopic follow-up. Given
limited exisiting data, more work must also be done to
inform providers of the optimal management approach
for patients with an abnormal FIT and a recent normal
colonoscopy. Additional research in these areas will im-
prove FIT screening programs, enhance management
and counseling of patients with abnormal FIT results,
and contribute to multimodal interventions to improve
colonoscopic follow-up after abnormal FIT.
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